Key Developments For Obagi Medical Products, Inc.
Obagi Medical Products, Inc. (OMPI.O) (Nasdaq)
Obagi Medical Products, Inc. Issues Q4 2009 Outlook In Line With Analysts' Estimates
Obagi Medical Products, Inc. announced that for fourth quarter of 2009, it expects revenue to be between $25.0-$27.0 million and earnings per fully diluted share (EPS) to be $0.16-$0.18. According to Reuters Estimates, analysts were expecting the Company to report revenues of $25.8 million and EPS of $0.16 for the same period.
Obagi Medical Products, Inc. Issues Q3 2009 Guidance; Revenue Guidance Above Analysts' Estimates
Obagi Medical Products, Inc. announced that based on current market conditions, the economic uncertainty and the Company's historical seasonality pattern, the Company expects revenue for the third quarter of 2009 to be between $24-26 million and earnings to be $0.13-$0.15 per fully diluted share. According to Reuters Estimates, analysts were expecting the Company to report revenue of $23 million and EPS of $0.14 for the third quarter of 2009.
Obagi Medical Products, Inc.' CLENZIderm M.D. Serum Gel Significantly Reduces Non-Inflammatory Lesions With Visible Results As Early As Week One
Obagi Medical Products, Inc. announced the successful completion of a 12-week study comparing CLENZIderm M.D.TM Serum Gel to a combination prescription benzoyl peroxide (BPO)/clindamycin product. The announcement was made at the American Academy of Dermatology`s (AAD) Summer Academy Meeting in Boston, MA. Of the 65 enrolled patients, 23 received four weeks of treatment (100 percent compliance) and 42 received 12 weeks of treatment (88 percent compliance). The data of the multicenter, investigator-blind, randomized, split-face study shows that patients with moderate facial acne vulgaris experienced significantly greater reductions in non-inflammatory lesions when using the CLENZIderm M.D. Serum Gel when compared to the leading topical BPO/clindamycin product.
Obagi Medical Products, Inc. Releases Results Of Clinical Trial Showing Optimized Patient Outcomes When Condition & Enhance System Is Used In Combination With Botulinum Toxin Type A
Obagi Medical Products, Inc. announced the positive study results at the American Academy of Dermatology`s (AAD) Summer Academy showing that the use of its Condition and Enhance System, when combined with Botulinum Toxin Type A treatments (BOTOX), provides greater improvement in overall facial appearance, as well as increased patient satisfaction, vs. BOTOX treatments with placebo. At the conclusion of the study, physician ratings of overall improvement in facial appearance were significantly greater with the Condition & Enhance System + BOTOX as compared to BOTOX with a standard skincare regimen. Also, it was found that 86% of Condition & Enhance + BOTOX patients achieved an overall improvement in facial appearance vs. 8% using BOTOX with a standard skincare regimen by the end of the trial. In addition, statistically significant benefits were seen in evenness of facial skin color tone and facial skin texture, as well as improved levels of skin laxity and fine lines and wrinkles.
Obagi Medical Products, Inc. Issues Q2 2009 Guidance Below Analysts' Estimates
Obagi Medical Products, Inc. announced that for second quarter 2009 it expects sales to be in the range of $22 - $24 million and fully diluted earnings per share to be $0.10 to $0.13. This guidance excludes the planned, pre-tax charge of $0.5 to $0.9 million to be taken in the second quarter of 2009 associated with termination of certain contracts related to exiting the pharmacy channel, or $0.01 to $0.03 per diluted share. According to Reuters Estimates, analysts are expecting the Company to report revenue of $26 million and EPS of $0.15 for second quarter 2009.
